Tubercular Drug Delivery Systems

The disability-adjusted life year (DALY) is a generic measure of health effect that can

be used in cost-effectiveness analysis as an alternative to the quality-adjusted life year

(QALY). Infectious diseases are one of the major to cause significant losses of DALY and

QALY. Human infectious diseases are disorders that are triggered by the microorganisms


such as bacteria, fungi, viruses, or parasites. The majority of such diseases are contagious


and create a public health menace. There are several reasons why infectious diseases

are deadly diseases, and one of the primary reasons is the drug resistance developed

over time. Drug resistance-associated mutations are linked to increasing drug efflux,

modifications of the drugs, or their targets. Every year, new drugs are being approved by

FDA to treat infectious diseases. Nonetheless, the infectious diseases will undoubtedly

persist as permanent and main threats to humanity now and in the future, primarily

due to increased longevity that almost always comes at a cost of impaired immunity.

A total of four books are covered under the series of Infectious diseases.


• Malarial drug delivery systems


• Tubercular drug delivery systems

• Viral drug delivery systems

• Infectious disease drug delivery systems

The theme of the second book is Tuberculosis (TB). This book addresses the recent

trends in drug delivery for treating TB using new formulation technologies, and the

mechanism how it can prevent or delay the drug resistance. It covers current drug therapy

and new drug targeting approaches focusing on innovative trend-defining technologies

and drug delivery platforms. It is essential to understand the relationship between host

pathogens for better treatment. Various novel and nano-formulations using promising


technologies are being explored to deliver TB drugs via different administration routes


at right pathological site. This book addresses the gap between new and old treatment

TB modalities and how they are superior in pharmacological performance when tested

in in-vitro and in-vivo.

Audiences from a broad range of groups, from researchers, academicians, and public


health bodies to regulatory experts, can benefit from the compiled information to learn


more about patient needs and current research advances in the field of TB research.